UroGen Pharma

UroGen

This biotech company develops sustained-release hydrogel treatments for urological cancers and sells them to specialist healthcare providers and clinics.

CG Oncology

This biopharmaceutical company develops oncolytic immunotherapies for patients with non-muscle invasive bladder cancer.

enGene

This clinical-stage biotechnology company develops non-viral gene therapies for patients with high-risk, non-muscle invasive bladder cancer and other mucosal tissue diseases.

Combat Medical

This company manufactures hyperthermic drug delivery systems for hospitals and oncology clinics to treat patients with bladder and peritoneal cancers.

Lipella Pharmaceuticals

This company develops reformulated generic drugs for patients with rare conditions, including hemorrhagic cystitis, oral lichen planus and bladder cancer.

Aura Biosciences

This biotechnology company develops virus-like drug conjugates to treat patients with solid tumours, specifically targeting ocular and bladder cancers.

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Convergent Genomics

This company develops non-invasive urine-based genomic tests to detect and monitor bladder cancer for clinicians and their patients.